Experimental stem cell therapy offers a potential breakthrough in treating frailty, a common condition in older adults that significantly increases the risk of falls, infections, and overall decline in quality of life. While current management relies on lifestyle interventions like exercise, new research suggests infusing stem cells from young, healthy donors into older individuals can measurably improve physical function.
The Science Behind the Treatment
The therapy, called laromestrocel, utilizes mesenchymal stem cells harvested from bone marrow donors aged 18 to 45. These versatile cells can develop into various tissues, including muscle and cartilage, and are designed to address the biological underpinnings of aging—specifically, chronic inflammation and impaired metabolic processes that weaken muscles.
A recent trial involving 148 participants aged 74 to 76 with mild-to-moderate frailty demonstrated that a single infusion of laromestrocel improved walking distance in a dose-dependent manner. Those receiving the highest dose could walk up to 63 meters further after nine months compared to the placebo group. This improvement in the six-minute walk test, a key measure of health status and longevity, is particularly significant given that frailty affects roughly 25% of individuals over 65.
How It Works: Regenerating Vascular Function
Researchers believe laromestrocel works by inhibiting matrix metalloproteinases, enzymes that degrade structural proteins in blood vessels and tissues. By suppressing these enzymes, the therapy may regenerate the vascular system, enhancing endurance-related muscle function.
Crucially, the trial also identified a potential biomarker for frailty: a blood fragment called sTIE2, which indicates impaired vascular function. Declining sTIE2 levels correlated with higher doses of laromestrocel, suggesting that individuals with elevated sTIE2 may benefit most from the treatment—potentially even before symptoms manifest. This personalized approach to geroprotector medicine—interventions that slow aging—could revolutionize how frailty is addressed.
Challenges and Future Outlook
Despite promising results, practical hurdles remain. The high cost of stem cell therapies and the logistical difficulties of sourcing sufficient donor cells are major concerns. Some experts question whether the benefits justify the expense compared to established interventions like structured walking programs, which have shown comparable improvements in walk distance.
However, biotechnology companies are actively developing scalable methods for stem cell production, aiming to make these therapies more accessible. As Joshua Hare of Longeveron explains, “There is a lot of work ongoing regarding the ability to make these kinds of stem cells in large quantities, and I am confident the need will be met.”
In conclusion, stem cell infusions represent a significant step toward biologically targeting frailty, potentially improving physical function and identifying individuals most likely to respond to treatment. While cost and scalability challenges exist, ongoing technological advancements suggest this approach could become a viable option for managing age-related decline in the future.
